Feline Pemphigus Foliaceus

Feline pemphigus foliaceus (PF) is one of the most common autoimmune skin diseases affecting cats, characterized by the immune-mediated formation of pustules, crusts, erosions, scales, and alopecia [1]. The disease is driven by immunoglobulin G (IgG) autoantibodies directed against the keratinocyte cell surface, particularly proteins of the desmosome junction, leading to a loss of cell-to-cell adhesion within the superficial epidermis [1][5]. First described in cats more than 30 years ago, feline PF has since been documented in numerous case reports and case series, steadily expanding clinical understanding of its presentation and management [2]. Unlike some human or canine counterparts, feline PF exhibits distinct clinical and immunological features that can make diagnosis and treatment uniquely challenging [3].

Feline PF is an autoimmune disease whose precise pathophysiology remains incompletely understood [1]. The central mechanism involves immune dysregulation leading to the production of IgG autoantibodies that target proteins expressed on the surface of keratinocytes, particularly those associated with the desmosomal complex—the intercellular adhesion structures responsible for maintaining epidermal integrity [1][5]. Loss of desmosomal adhesion, a process termed acantholysis, results in separation of individual keratinocytes within the superficial epidermis, forming the characteristic subcorneal pustules filled with non-degenerate neutrophils and acantholytic cells [4].

In humans and dogs with PF, the primary autoantigen is desmoglein-1 (Dsg1), a desmosomal cadherin. However, circulating anti-Dsg1 antibodies have not been consistently detected in feline PF, suggesting that the target antigen(s) in cats may differ from other species [3]. A study using indirect immunofluorescence and ELISA confirmed the presence of circulating anti-keratinocyte IgG autoantibodies in PF-affected cats, but the precise antigenic targets remain to be fully characterized [3].

Triggering factors are not clearly established in all cases. Some cases of feline PF appear to be idiopathic, while others have been associated with prior drug exposure, underlying chronic disease, or other immune-activating stimuli [2]. There is no definitive breed, sex, or age predisposition firmly established, though the disease has been reported across a wide age range [2][6]. The fundamental immune dysregulation appears to result in autoreactive B-cell clones producing pathogenic IgG, which, upon binding to keratinocyte surfaces, activate downstream inflammatory cascades—including neutrophil recruitment and protease-mediated disruption of intercellular adhesion [1].

Diagnosis of feline PF relies on integration of clinical presentation, cytological findings, and histopathological confirmation [4].

Clinical Assessment A characteristic distribution of lesions—particularly crusts and pustules involving the pinnae, nasal planum, periocular area, chin, and feet—in a cat should raise strong suspicion for PF [4][6]. Identification of intact pustules, though often difficult because of their transient nature, is particularly valuable.

Cytology Fine-needle aspiration or impression smears of pustules or beneath freshly lifted crusts frequently reveal acantholytic keratinocytes—large, rounded epithelial cells with prominent nuclei that have lost their intercellular connections—admixed with non-degenerate neutrophils [4]. While acantholytic cells are a hallmark finding, they are not pathognomonic for PF and may be seen in other pustular conditions, so cytology alone is insufficient for definitive diagnosis [4].

Histopathology Skin biopsy with histopathological examination remains the gold standard for diagnosis. The characteristic finding is subcorneal or intragranular pustule formation containing non-degenerate neutrophils and acantholytic keratinocytes [4][6]. Sampling of intact or early pustules rather than crusted lesions improves diagnostic yield. When owners decline biopsy, alternative non-invasive sampling methods (e.g., tape-strip histology) have been explored in some cases [5].

Immunofluorescence and Serology Indirect immunofluorescence (IIF) can detect circulating anti-keratinocyte IgG autoantibodies in a subset of affected cats; one study using IIF and ELISA found detectable autoantibodies in PF-affected cats compared to healthy and allergic controls, supporting an autoimmune pathogenesis [3]. However, serological testing is not yet a routine diagnostic tool in clinical practice because sensitivity and target antigens remain incompletely characterized [3].

Laboratory Findings Routine clinicopathological changes are not specific but may support the diagnosis and help guide therapy:

• ·Complete Blood Count (CBC): Leukocytosis with neutrophilia may be present, reflecting systemic inflammation or secondary infection. Eosinophilia has been noted in some cases [6].
• ·HCT (Hematocrit): Mild anemia (low HCT) can develop in chronic or severely affected animals [6].
• ·PLT (Platelets): Generally within normal limits unless concurrent disease is present.
• ·Serum Biochemistry: Elevations in globulins (GLOB) reflecting chronic immune stimulation may be observed. Albumin (ALB) may be mildly decreased in chronic disease. Liver enzymes (ALT) and kidney parameters (BUN, CREA) should be monitored as baselines prior to immunosuppressive therapy and during long-term treatment, as medications such as glucocorticoids and chlorambucil carry risks of organ toxicity [6][7].
• ·TBIL: Not typically elevated unless hepatic disease is concurrent.

Differential Diagnoses Conditions to rule out include dermatophytosis, demodicosis, bacterial pyoderma, drug eruption, and other immune-mediated dermatoses [2][4].

The cornerstone of feline PF management is long-term, often lifelong, immunosuppressive therapy [1][2]. Because the disease involves pathogenic autoantibody production, suppressing the aberrant immune response is necessary to control clinical signs.

Glucocorticoids

High-dose prednisolone or methylprednisolone is typically the first-line treatment. Induction doses are used until remission is achieved, followed by gradual tapering to the lowest effective maintenance dose [1][4][6]. Dexamethasone or triamcinolone may be used in cats that are difficult to medicate orally. Long-term glucocorticoid use carries risks including diabetes mellitus, infection susceptibility, muscle wasting, and hepatopathy, necessitating regular monitoring of blood glucose, ALT, and body weight.

Chlorambucil

Chlorambucil (an alkylating chemotherapeutic agent used as an immunosuppressant) is one of the most commonly used adjuvant drugs in feline PF, particularly when glucocorticoids alone are insufficient or when steroid side effects are problematic [2][7]. It is typically combined with prednisolone and has been reported to achieve remission or significant improvement in a proportion of cats. Bone marrow suppression is the primary adverse effect; monitoring of CBC (particularly WBC and PLT) is essential during treatment [7].

Cyclosporine (Ciclosporin)

Modified cyclosporine has been evaluated as both a sole immunomodulatory agent and as an adjuvant to other therapies. A retrospective study found that cyclosporine-treated cats had comparable outcomes to chlorambucil-treated cats in some parameters, offering an alternative for cases where chlorambucil is not tolerated [7]. Gastrointestinal side effects and nephrotoxicity (elevated CREA, BUN) warrant monitoring.

Oclacitinib

Oclacitinib (a Janus kinase [JAK] inhibitor) has been reported in at least one case of feline PF to successfully control clinical signs, suggesting a potential therapeutic role in cases refractory to conventional immunosuppression [8]. While evidence is currently limited to case-level reports, this represents a potentially valuable alternative to high-dose glucocorticoids in select patients [8].

Topical Therapy

Topical hydrocortisone aceponate spray has been used successfully in at least one reported case of feline PF, either alone or in combination with pentoxifylline, resulting in disease control without systemic immunosuppression [5]. This approach may be particularly valuable in cats where systemic drug administration is problematic or where owners wish to minimize systemic side effects [5].

Pentoxifylline

Pentoxifylline, a methylxanthine derivative with immunomodulatory and anti-inflammatory properties, has been used in combination with topical steroids with reported success [5]. Its mechanism in PF involves reduction of cytokine production and modulation of neutrophil function.

Supportive Care

• ·Antiseptic shampoos or wipes to reduce bacterial bioburden in crusted areas
• ·Antibiotics when secondary bacterial infection is confirmed or suspected
• ·Environmental modifications to prevent trauma to fragile, crusted skin
• ·Regular rechecks including CBC, serum chemistry (ALB, GLOB, ALT, BUN, CREA, glucose) every 1–3 months during immunosuppressive therapy to detect drug-related adverse effects [6][7]

The prognosis for feline PF is variable and depends on disease severity, response to therapy, and the cat's ability to tolerate long-term immunosuppression [2][6].

Overall Outcome Data A study of 49 cats with PF examined over a 30-year period at a veterinary teaching hospital in Northern California provided the most comprehensive outcome data available [6]. Long-term disease management is typically required, as PF is generally considered a chronic, lifelong condition rather than one that resolves permanently [1][2].

In the large literature review and original case series by Bizikova and Burrows (2019), a substantial proportion of cats achieved remission or significant clinical improvement with appropriate immunosuppressive therapy, but a meaningful subset required ongoing treatment adjustments, experienced relapses, or were euthanized due to uncontrolled disease or treatment-related complications [2]. Quality of life was reported to be negatively affected in many cases, though a proportion of owners reported their cats living comfortably with managed disease [6].

Mortality Considerations Feline PF itself is not immediately life-threatening in most cases, but severe, refractory disease or complications of immunosuppressive therapy (e.g., opportunistic infections, drug-induced diabetes mellitus, bone marrow suppression from chlorambucil) can lead to significant morbidity and mortality [2][6][7]. Euthanasia due to poor quality of life or unmanageable disease has been reported in a portion of cases across clinical series [6]. The reviewed literature does not provide a single consolidated mortality percentage; however, the disease carries a guarded to good prognosis in cats that respond well to therapy, and a guarded to poor prognosis in those with severe or treatment-refractory disease.

Remission and Relapse Complete remission (off all therapy) is possible but uncommon; most cats require lifelong maintenance therapy [1][2]. Relapses during tapering of immunosuppressive drugs are frequent and should be anticipated in the management plan [2][6].

There are currently no known vaccines or specific preventive measures for feline pemphigus foliaceus, as the disease is autoimmune in nature and not caused by an infectious agent [1][2].

• ·Avoidance of triggering drugs: In cases where PF has been temporally associated with specific drug administration, future avoidance of those agents may reduce the risk of recurrence. Owners should inform all treating veterinarians of the PF diagnosis and prior triggers [2].
• ·Minimizing immune dysregulation: While not proven to prevent PF, maintaining overall feline health through appropriate vaccination protocols, parasite control, dental care, and management of concurrent chronic diseases may reduce the burden of systemic immune activation.
• ·Genetic considerations: Given the autoimmune basis of the disease, breeding from affected animals is generally discouraged, though definitive heritable risk factors in cats have not been established.
• ·Early recognition and monitoring: Cats with a known history of PF or close relatives with autoimmune disease should be monitored closely for early cutaneous signs so that treatment can be initiated promptly if the disease develops or relapses.
• ·Drug exposure awareness: Some cases of feline PF have been linked to prior drug exposure; judicious use of medications and careful monitoring of skin reactions following new drug introduction is advisable [2].